Contractions in human coronary bypass vessels stimulated by extracellular nucleotides.
BACKGROUND
The present study was designed to evaluate the relative contribution of different contractile P2 receptors in human saphenous vein compared with internal mammary artery obtained during coronary artery surgery.


METHODS
The isometric tension in endothelium-denuded isolated vessel segments was recorded in vitro. The P2 receptor mRNA expression was quantified by real-time polymerase chain reaction.


RESULTS
The P2X(1) receptor agonist, alphabeta-MeATP (alphabeta-methylene-adenosine triphosphate), was the most potent vasoconstrictor, with more efficacious contractions in the saphenous vein than in the internal mammary artery. The selective P2Y(6) receptor agonist, UDPbetaS (uridine 5'-O-thiodiphosphate), stimulated more potent contractions in saphenous vein compared with internal mammary artery. Furthermore, UDPbetaS induced long-lasting contractions for more than 2 hours, explained by the low desensitization rate of the P2Y(6) receptor. The ATP-induced vasoconstriction could not be abolished by desensitization of P2X(1) receptors with alphabeta-MeATP, or P2Y(2/4) receptors with UTPgammaS (uridine 5'-O-3-thiotriphosphate), indicating the presence of yet another contractile ATP receptor. Based on quantification with real-time polymerase chain reaction, the P2Y(11) receptor could be responsible for this ATP contraction.


CONCLUSIONS
The P2X(1) and P2Y(6) receptors elicit more prominent contractions in the saphenous vein as compared with the internal mammary artery. These results may present one explanation for the differences in the two conduits. It is possible that selective antagonists of P2X(1) and P2Y(6) receptors could be used to prevent vasospasm and restenosis in the saphenous vein during and after revascularization surgery.
Borna
Catharina
C
department of Cardiology, University Hospital, Lund, Sweden.
Wang
Lingwei
L
Gudbjartsson
Tomas
T
Karlsson
Lena
L
Jern
Sverker
S
Malmsjö
Malin
M
Erlinge
David
D
D000368:Aged; D001026:Coronary Artery Bypass / Q000379:methods; D003327:Coronary Disease / Q000473:pathology / Q000601:surgery; D003331:Coronary Vessels / Q000187:drug effects / Q000502:physiology; D046508:Culture Techniques; D005260:Female; D006801:Humans; D008297:Male; D008323:Mammary Arteries / Q000187:drug effects / Q000502:physiology*; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology; D009711:Nucleotides / Q000494:pharmacology*; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012501:Saphenous Vein / Q000187:drug effects / Q000502:physiology*; D012680:Sensitivity and Specificity; D014661:Vasoconstriction / Q000187:drug effects* / Q000502:physiology*; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology
D009711:Nucleotides; D012333:RNA, Messenger